Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 4, 1997, Pages 464-475

  Lewis, Lionel D ^a   Benin, Andrea ^b   Szumlanski, Carol L ^b   Otterness, Diane M ^b   Lennard, Lynne ^b   Weinshilboum, Richard M ^b   Nierenberg, David W ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; FLUOXETINE; MERCAPTOPURINE; METHYLPREDNISOLONE; METRONIDAZOLE; OLSALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE;

ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CROHN DISEASE; ENZYME ACTIVITY; ERYTHROCYTE; GENOTYPE; HUMAN; HUMAN CELL; LEUKOPENIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE COUNT;

6-MERCAPTOPURINE; ADOLESCENT; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS; BONE MARROW; CROHN DISEASE; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREDNISONE;

EID: 0030657957     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90125-9     Document Type: Article

References (30)

1. Griffin MG, Miner PB. Conventional drug therapy in inflammatory bowel disease. Gastroenterol Clin North Am 1995;24:509-21.
2. Hanauer SB. Drug therapy: inflammatory bowel disease. N Engl J Med 1996;334:841-8.
3. Present D, Korelitz B, Wisch N, Sacher D, Pasternack B. Treatment of Crohn's disease with 6-mercaptopurine: a long term, randomized double blind study. N Engl J Med 1980;302:981-7.
4. Wadworth AN, Fitton A. Olsalazine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in inflammatory bowel disease. Drugs 1991;41:647-64.
5. Kruis W, Judmaier G, Kayasseh L, Stolte L, Theuer D, Scheurlen C, et al. Double blind dose finding study of olsalazine versus sulfasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7:391-6.
6. Pharmacia-Adria Ltd. Dipentum: olsalazine sulfate. In: Physicians desk reference. 49th ed. Oradell, NJ: Medical Economics; 1995. p. 1888-90.
7. Present BH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz KI. 6-Mercaptopurine in the management of inflammatory bowel disease: short and long term toxicity. Ann Intern Med 1989;111:641-59.
8. Bernstein CN, Artinian L, Anton PA, Shanahan F. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci 1994;39:1638-41.
9. Connell WM, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years experience. Gut 1993;34:1081-5.
10. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang P, Chabner B, et al. Variable bioavailability of oral mercaptopurine. N Engl J Med 1983;308:1005-7.
11. Patterson ARP, Tidd DM. 6-Thiopurines. In: Sartorelli AC, Johns DG, editors. Antineoplastic and immunosuppressive agents. 2nd ed. New York: Springer-Verlag;1975. p. 384-403.
12. Remy CN. Metabolism of thiopyrimidines and thiopurines: S-methylation and S-adenosylmethionine transmethylase and catabolism in mammalian tissue. J Biol Chem 1963;238:1078-84.
13. Woodson LC, Weinshilboum RM. Human kidney thiopurine methyltransferase: purification and biochemical properties. Biochem Pharmacol 1983;32: 819-26.
14. Kooij A, Schijns M, Frederiks WM, Van Noorden CJ, James J. Distribution of xanthine oxidoreductase in human tissues: a histochemical and biochemical study. Virchows Arch 1992;63:17-23.
15. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte methyltransferase activity. Am J Hum Genet 1980;32: 651-62.
16. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46: 149-54.
17. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456-9.
18. Woodson LC, Ames MM, Selassie CD, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol 1994;24:471-8.
19. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323-33.
20. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992;2:148-59.
21. Honchel R, Aksoy L, Szumlanski C, Wood TC, Otterness DM, Wieben ED, et al. Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol Pharmacol 1993;43:878-87.
22. Wilkinson GN. Statistical estimations in enzyme kinetics. Biochem J 1961;80:324-32.
23. Cleland WW. Computer programmes for processing enzyme kinetic data. Nature 1963;198:463-5.
24. Segal IH. Enzyme kinetics. New York: John Wiley; 1975. p. 274-82.
25. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah J, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62:60-73.
26. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1990;336:225-9.
27. Giverhaug T, Klemetsdal B, Lysaa R, Aarbakke J. Intraindividual variability in red blood cell thiopurine methyltransferase activity. Eur J Clin Pharmacol 1996;50:217-20.
28. Christensen LA, Fallinborg J, Jacobsen BA, Abildgaard K, Rasmussen HH, Hansen SH, et al. Comparative bioavailability of 5-aminosalicylic acid from a controlled preparation and an azo bond preparation. Aliment Pharmacol Ther 1994;8:289-94.
29. Staerk Laursen L, Stokholm M, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal coIonic concentrations, serum values and urinary excretion. Gut 1990;31:1271-6.
30. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai H, Pui C, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.